NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who acquired Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) securities between February 23, 2016 and March 18, 2016 (the “Class Period”).
The lawsuit alleges that throughout the Class Period, defendants failed to disclose that the U.S. Food and Drug Administration (“FDA”) would not approve KANGIO, a blood thinning drug, in its present form and would need additional information regarding the substances used in KANGIO.
On March 18, 2016, the company revealed that the FDA had issued a Complete Response Letter stating that it could not approve the drug application for KANGIO in its current form and requesting further characterization of bivalirudin-related substances in the drug.
Following this news, Eagle stock dropped over $10.00 per share to close at $43.50 on March 18, 2016.
If you held Eagle securities during the Class Period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at email@example.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.